Clin Cancer Res 2024 Oct 1
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Related Questions
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (November 24, 2024)
EMERALD study enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one or two lines of endocrine therapy, required pretreatment with a CDK4/6i, and ...